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Lille, FranceAbstractThe diagnosis of systemic Candida infections is a recognized
challenge. We developed a mass spectrometry strategy to detect
signals from Candida molecules in patients’ sera. Pre-analytical
procedures were designed to extract oligosaccharides from
serum. A peak m/z of at 365 was speciﬁcally revealed in sera
from patients with candidaemia with regard to healthy controls.
This biomarker was identiﬁed as a disaccharide, its presence did
not correlate with mannanaemia or glucanaemia. Mouse models
of Candida albicans colonization and infection showed that the
signal was speciﬁcally associated with tissue invasion, suggesting
that clinical evaluation of its usefulness in discriminating colonized
and infected patients would be worthwhile.
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p://dx.doi.org/10.1016/j.cmi.2014.08.010IntroductionDespite considerable progress in antifungal therapy, the
morbidity and mortality of invasive candidiasis remain high,
particularly in the intensive care unit [1]. This is due to the
difﬁculties in diagnosis of these infections, which needs to
be early for a favourable outcome. In contrast to bacterial
infections, blood cultures dramatically lack sensitivity (50%)
[2]. Facing this problem, methods for the detection of fungal
molecules circulating in the sera of infected patients have
been developed, some of which are now recommended by
infectious disease societies as diagnostic alternatives or ad-
juncts [3]. These tests detect Candida cell wall glycans (i.e.
polysaccharides and polysaccharide moieties of glycoproteins
and glycolipids), comprising mannans and glucans, by appli-
cation of immunocapture and biochemical methods,
respectively [4]. We present here a preliminary description
of an innovative physicochemical approach developed for
detecting circulating fungal glycans among the complex
serum environment by using matrix-assisted laser desorp-
tion/ionization time-of-ﬂight mass spectrometry (MALDI-
TOF MS).Patients and methodsSera from patients with Candida infection and controls
Sera were selected from the clinical mycology laboratory
database from patients with candidaemia and for whom sera
around the time of the infection were available. Sera were
selected primarily from patients infected with Candida albicans
(11 patients, 15 sera), but also from patients with candidaemia
episodes due to Candida glabrata (n = 2), Candida parapsilosis
(n = 3), Candida tropicalis (n = 2), Candida krusei, Candida dub-
liniensis and Candida lusitaniae (n = 1) to cover the spectrum of
the most frequent blood isolates. Altogether, 25 sera were
selected from 21 patients (7 females and 14 males; median age
55 years, range: 30–75 years) hospitalized on the intensive care
unit (n = 18), on a geriatric ward (n = 1) or on a haematology
unit (n = 2). Sera were drawn between 2 weeks before and 2
weeks after the isolation of Candida species in blood culture
(median delay of sampling: 4 days after positive blood culture).
The clinical charts of these patients were then reviewed to
conﬁrm that they were suffering from invasive candidiasis. The
presence of circulating glucans and mannans was also
determined.
Control sera consisted of 21 sera from healthy blood donors
(Etablissement Français du Sang, Lille, France).ious Diseases. Published by Elsevier Ltd. All rights reserved
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All the sera used in this study were sampled from patients
followed in Lille University Hospital. No additional sampling was
necessary. As sera were taken from a registered biological
collection, according to French law, patients consent was not
required. An institutional review board approval was given by
the ‘Comité de Protection des Personnes Nord-Ouest IV’.
Animal models
Six-week-old to 8-week-old female C57BL/6 mice were main-
tained by Charles River Laboratories (L’Arbresle, France). Ex-
periments were approved by the Subcommittee on Research
Animal Care of the Regional Hospital Centre of Lille, France,
and in accordance with the European guidelines (86/609/CEE).
To induce colonization, ten mice were given 1.5% dextran
sulphate sodium (DSS; MW 36–50 kDa; MP Biomedicals,
Eschwege, Germany) in drinking water from day 1 to day 14 to
induce intestinal inﬂammation, and inoculated on the same day
by oral gavage with 200 mL of phosphate-buffered saline con-
taining 107 C. albicans SC5314 strain [5,6].
To induce systemic candidiasis, ten mice were injected with
104 yeasts from the same strain in 0.1 mL sterile saline via the
tail vein. Mice were monitored daily for 14 days and killed by
cervical dislocation. Blood was collected by cardiac puncture.
A total of 60 mice were divided into two experimental
groups and each experiment is composed of infected mouse
with C. albicans (10 mice/cage), mice receiving DSS alone (10
mice/cage), and DSS+ C. albicans (10 mice/cage).
Controls for colonization/infectionweremade by ﬂuorescence
staining ofC. albicanson colon and kidney parafﬁn sections by using
the anti-C. albicans monoclonal antibody 5B2 [5]. The sections,
counterstained with Evans blue and DAPI, were examined with
immunoﬂuorescence and confocal microscopy (Leica Micro-
systems AG; Zeiss LSM710, diode 561 nm DPSS, respectively).
Measurement of mannan and glucan polysaccharides in
clinical samples
Serum β-1,3-glucan was measured using a Fungitell® kit (Asso-
ciates of Cape Cod Inc., Falmouth, MA, USA) and measurement
of serum mannan was performed using the Platelia Candida®
Ag+ test (Bio-Rad, Marnes la Coquette, France) according to the
manufacturers’ instructions. The cut-off values of serum β-1,3-
glucan and mannan were 80 pg/mL and 125 pg/mL, respectively.
Pre-analytical procedures
Sera were treated as described previously [7]. Brieﬂy, 300 μL of
serum and 100 μL of Na2-EDTAwere added in Eppendorf tubes,
vortexed vigorously and heated at 120°C for 6 min. Samples
were centrifuged at 10000 g for 10 min and the supernatants
were collected. Soluble oligosaccharides were then enrichedClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology andfrom supernatant by afﬁnity and reverse-phase chromatography;
100 μL of supernatant was applied to a homemade mixed-bed
chromatography column made by packing 60 μL of activated
charcoal-celite (50 : 50 by weight) in a 1.5-mL reservoir car-
tridge ﬁtted with a 5-mm polyethylene frit, and then 60 μL of RP
medium (Sepra ZT 30 μm, 85 A; Phenomenex, Torrance, CA,
USA). The column was conditioned by washing with ethanol/
water 20 : 80 (volume/volume) and equilibrating with water.
After loading the sample, the column was washed with 4 mL of
water and the oligosaccharide fraction was eluted with 600 μL of
5% ethanol. The solution was dried down under vacuum and
resuspended in 40 μL water.
Detection by mALDI-TOF MS
An ionic liquid matrix (2,5-dihydrobenzoic acid-pyridine (DHB-
Py)) was chosen over a classic DHB matrix for better homo-
geneity, which is a crucial factor for reproducibility in quanti-
tative analyses. This ionic liquid matrix was prepared by adding
4 μL of pyridine to 1 mL of acetonitrile/water/triﬂuoroacetic
acid (50 : 50 : 0.1, by volume) solution with 7.7 mg of DHB,
which yielded a 1 : 1 molar ratio of pyridine : DHB. One
microlitre of puriﬁed serum was then spotted onto the MALDI
plate followed by 1 μL of DHB-Py preparation. The sample
spots were dried by heating at 50°C for 2 min.
Analysis was performed using an AB (Applied Biosystems/MDS
Sciex, Concord,ON, Canada) 4800MALDI-TOF/TOF analyser at
ﬁxed laser intensity for 1000 shots/spectrum. In total, 3000 shots
were accumulated in reﬂectron positive ion mode MS for each
sample. Signals were registered between m/z 300 and 800.
Statistical analysis
Mann–Whitney two-tailed tests were used to compare the
distribution of 365/361 ratios between patients with candi-
daemia and healthy subjects.ResultsEnrichment of oligosaccharides and identiﬁcation of an
oligosaccharide marker
The development steps of the research comprised a pre-
analytic process to purify serum oligosaccharides by heat
treatment initially described for releasing fungal glycans from
complexes with serum compounds and eliminate interference
in their biochemical detection [7]. The clear supernatant still
contains heat-stable glycans but is devoid of the vast majority of
proteins and lipids, which are trapped in the coagulum. Omis-
sion of heat treatment prevented the detection of any oligo-
saccharide in the samples. A two-phase chromatography
process enriched the oligosaccharide fraction to increase theInfectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 88.e1–88.e6
FIG. 2. Structural analysis of the disaccharide from a patient with
candidaemia. Disaccharide-containing puriﬁed serum was per-
methylated as described by Ciucanu and Kerek (Carbohydrate Res
1984;131:209–17) and analysed by matrix-assisted laser desorption/
ionization time-of-ﬂight (MALDI-TOF) mass spectrometry (MS).
MALDI-TOF spectrum of permethylated serum shows a signal at m/z
477 corresponding to [M+Na]+ of permethylated Hex2.
88.e3 Clinical Microbiology and Infection, Volume 21 Number 1, January 2015 CMIsignal to noise ratio. Residual proteins and lipids were ﬁrst
removed by reverse-phase solid-phase extraction whereas free
glucose and salts were removed by afﬁnity solid-phase extrac-
tion on activated charcoal. Oligosaccharides were eluted and
dried under vacuum. Samples were analysed in reﬂectron mode
using MS parameters previously established for the analysis of
puriﬁed C. albicans cell-wall-derived oligoglucosides [6]. MALDI-
TOF spectra of sera from healthy controls and patients with
candidaemia revealed the presence of a prominent signal at m/z
365 observed in all patients’ sera (Fig. 1a) that was absent or
present at a much reduced intensity in control sera (Fig. 1b).
This signal was tentatively attributed to an [M+Na]+ adduct of
Hex disaccharide. In order to conﬁrm the disaccharide nature
of the signal observed at m/z 365, treated samples were per-
methylated by the NaOH/ICH3 slurry method [8] and extrac-
ted by chloroform/water partitioning. MALDI-TOF spectra of
permethylated sera showed a candidiasis patient-speciﬁc signal
at 477 m/z (Fig. 2) corresponding to the [M+Na]+ adduct of
permethylated Hex2 disaccharide, which conﬁrmed the previ-
ous attribution of signal at 365 m/z as Hex2. Altogether, puri-
ﬁcation steps and structural analysis established the presence of
Hex disaccharide, in sera from patients with candidaemia.
Potential clinical value
The 25 sera from 21 patients with candidaemia and 21 control
sera were analysed following the established protocol.FIG. 1. (a, b) Representative example of matrix-assisted laser desorption/ioni
signal in puriﬁed sera from patients with candidaemia (a) in comparison with
ratio determined by MALDI-TOF in 25 sera from 21 patients with candidaemi
experiments.
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and InfectConsideration of spectra revealed an m/z 361 peak originating
from the matrix (Fig. 1a, b) and attempts to use the 365/361
ratio gave highly reproducible results in differentiating patients
and controls. The distribution of these values, is shown in
Fig. 1(c); 365/361 median (interquartile range; 25–75) values of
174 (71–206) and 23 (17–30) were calculated for the patients
and controls, respectively (p <0.0001). The 365/361 ratio did
not correlate with glucan nor mannan contents of sera (Fig. 3a,
b, respectively).zation time-of-ﬂight (MALDI-TOF) mass spectra containing the m/z 365
healthy subjects (b). (c) Comparison of the distribution of the 365/361
a and 21 healthy controls. The values are the mean of three independent
ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 88.e1–88.e6
FIG. 3. Correlation between the ra-
tio of 365/361 signals with (a) gluca-
naemia and (b) mannanaemia as
determined by using commercially
available diagnostic tests.
CMI Sendid et al. Serum disaccharide and Candida albicans infection 88.e4Conﬁrmation of results in mice
Because human invasive candidiasis is a disease that evolves
quickly over time, from colonization to invasion, we designed
an in vivo animal model to conﬁrm the speciﬁcity of the signalFIG. 4. (a) Matrix-assisted laser desorption/ionization time-of-ﬂight (MALD
puriﬁcation procedure. (a) Pooled control sera from BALB/c mice treated w
mice treated with DSS and colonized with Candida albicans following oral ad
infected by intravenous injection of C. albicans and killed on day 14. The arr
infection. (b’, c’) Immunoﬂuorescent labelling of C. albicans in the correspondin
kidneys electively leading to the observation of m/z 365 signal. Scale bar 10 μ
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology andfor invasion. We chose mice because they can either be heavily
colonized or infected intravenously. Ten BALB/c mice were
colonized by C. albicans by using the DSS model. Ten more mice
were injected intravenously with the same C. albicans strain.I-TOF) spectra of sera from mice after application of the enrichment/
ith dextran sulphate sodium (DSS) alone; (b) pooled sera from BALB/c
ministration and killed on day 14; (c) pooled sera from BALB/c mice
ow indicates the signal at m/z 365 observed speciﬁcally after systemic
g experiments (b’) colonization of mouse gut; and (c’) invasion of mouse
m.
Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 88.e1–88.e6
88.e5 Clinical Microbiology and Infection, Volume 21 Number 1, January 2015 CMIImmunohistological examination conﬁrmed the presence of
large amounts of C. albicans yeasts in the gut of colonized mice
(Fig. 4b’) and the absence of organ invasion, whereas infected
animals displayed C. albicans yeasts and hyphae invading organs
(Fig. 4c’). The two corresponding serum pools (Fig. 4b,c) and a
control pool from uninfected mice (Fig. 4a) were subjected to
the same extraction/puriﬁcation procedure and MS analysis as
the human sera. The m/z 365 signal was only observed in sera
from mice that developed a C. albicans systemic infection.DiscussionInvasive candidiasis is associated with high morbidity and is a
frequent cause of mortality among hospitalized patients who
receive intensive management. A combination of risk factors,
well known by clinicians [9], results in a transient disruption of
homeostasis leading to proliferation of C. albicans in the intes-
tine and dissemination [10]. Unfortunately, blood cultures are
only positive in 50% of patients with invasive candidiasis [2]. As
early diagnosis is essential to reduce mortality, infectious dis-
ease societies recommend the use of non-culture-based
methods to complement blood culture and assist in therapeu-
tic decisions. Among these surrogate markers, Candida cell wall
polysaccharides can be measured in sera from patients with
invasive candidiasis. These consist of mannan, non-covalently
associated to the cell wall outer layers, and β-D,1-3-glucan
making up the ﬁbrils in the cell wall middle layers [11]. These
glycans can be detected using immunological and biochemical
tests, respectively. Both methods now detect molecules in the
range of pg/mL with high reliability [4] and may be comple-
mentary [12].
Our aim was to seek new biomarkers with a physicochemical
approach. The pre-analytical treatment led to puriﬁcation/con-
centration of soluble fungal oligosaccharides [6,7]with a dramatic
reduction in signals originating from serum. The spectrum anal-
ysis revealed a speciﬁc signal atm/z 365 in sera from patients with
candidaemia which was quantiﬁed with regard to a signal at m/z
361 corresponding to a matrix peak used as a reference. Per-
methylation of patients conﬁrmed its disaccharide nature. Hence,
beside proteins and polysaccharides, our study shows for the ﬁrst
time that Hex2 disaccharides are among the fungal molecules
circulating during human invasive candidiasis. Conﬁrmation of
this circulation was gained by experimental models. Comparison
of mouse colonization and systemic infection in a blind analysis
provided evidence for the speciﬁc association of the m/z 365
signal with systemic Candida infection [9].
From the clinical point of view, this preliminary ﬁnding is of
interest for clinical context where discrimination between gut
colonization and infection is not clear-cut. The presence ofHex2 isClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectnot correlated with those of mannans and glucans and may open
new doors to IC diagnosis and patient management. Its clinical
value remains to be established through large prospective studies.
From a technical point of view, MALDI MS is now part of
daily practice in clinical microbiology laboratories. Its applica-
tions range from microbe identiﬁcation to the determination of
sensitivity to antifungal drugs [13]. However, up to now no
application has concerned the detection of microbe-derived
molecules in sera for diagnostic purposes. The method does
not involve enzymes or antibodies, is rapid, simple, cheap and
adapted to the survey of large numbers of patients’ sera.
From a basic point of view, there is still progress to be made
in the detection and characterization of glycans synthesized by
fungi that could circulate in human sera and have immunological
roles [14]. The goals of identifying these molecular species are
theoretically accessible to the method described.Transparency DeclarationCompeting interests: All authors report no potential conﬂicts
of interest.AcknowledgementsThe research leading to these results has received funding from
the European Community’s Seventh Framework Programme
(FP7-2007-2013) under HEALTH-F2-2010-260338-ALLFUN.
This work was also supported by the Programme Hospitalier de
Recherche Clinique du Ministère des Affaires Sociales, de la
Santé et de la Ville PHRC 1918, 2011 « Candigène ». We thank
Val Hopwood, val@langmed.co.uk, for writing assistance.References[1] Mean M, Marchetti O, Calandra T. Bench-to-bedside review: Candida
infections in the intensive care unit. Crit Care 2008;12:204.
[2] Clancy CJ, Nguyen MH. Finding the “missing 50%” of invasive candi-
diasis: how nonculture diagnostics will improve understanding of dis-
ease spectrum and transform patient care. Clin Infect Dis 2013;56:
1284–92.
[3] Pappas PG, Kauffman CA, Andes D, Benjamin Jr DK, Calandra TF,
Edwards Jr JE, et al. Clinical practice guidelines for the management of
candidiasis: 2009 update by the Infectious Diseases Society of America.
Clin Infect Dis 2009;48:503–35.
[4] Marchetti O, Lamoth F, Mikulska M, Viscoli C, Verweij P, Bretagne S,
European Conference on Infections in Leukemia (ECIL) Laboratory
Working Groups. ECIL recommendations for the use of biological
markers for the diagnosis of invasive fungal diseases in leukemic pa-
tients and hematopoietic SCT recipients. Bone Marrow Transpl
2012;47:846–54.ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 88.e1–88.e6
CMI Sendid et al. Serum disaccharide and Candida albicans infection 88.e6[5] Jawhara S, Thuru X, Standaert-Vitse A, Jouault T, Mordon S, Sendid B,
et al. Colonization of mice by Candida albicans is promoted by chem-
ically induced colitis and augments inﬂammatory responses through
galectin-3. J Infect Dis 2008;197:972–80.
[6] Jawhara S, Habib K, Maggiotto F, Pignede G, Vandekerckove P, Maes E,
et al. Modulation of intestinal inﬂammation by yeasts and cell wall
extracts: strain dependence and unexpected anti-inﬂammatory role of
glucan fractions. PloS one 2012;7:e40648.
[7] Sendid B, Francois N, Decool V, Poissy J, Poulain D. Strategy for
overcoming serum interferences in detection of serum (1,3)-β-d-glu-
cans. J Clin Microbiol 2013;51:375–6.
[8] Ciucano I, Kerek F. A simple and rapid method for the permethylation
of carbohydrates. Carbohydrate Res 1984;131:209–17.
[9] Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a
persistent public health problem. Clin Microbiol Rev 2007;20:133–63.Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and[10] Voss A, Hollis RJ, Pfaller MA, Wenzel RP, Doebbeling BN. Investigation
of the sequence of colonization and candidemia in nonneutropenic
patients. J Clin Microbiol 1994;32:975–80.
[11] Latge JP. The cell wall: a carbohydrate armour for the fungal cell. Mol
Microbiol 2007;66:279–90.
[12] Held J, Kohlberger I, Rappold E, Busse Grawitz A, Hacker G. Com-
parison of (1-3)-β-d-glucan, mannan/anti-mannan antibodies, and
Cand-Tec Candida antigen as serum biomarkers for candidemia. J Clin
Microbiol 2013;51:1158–64.
[13] Posteraro B, De Carolis E, Vella A, Sanguinetti M. MALDI-TOF mass
spectrometry in the clinical mycology laboratory: identiﬁcation of fungi
and beyond. Expert Rev Proteomics 2013;10:151–64.
[14] Netea MG, Brown GD, Kullberg BJ, Gow NA. An integrated model of
the recognition of Candida albicans by the innate immune system. Nat
Rev Microbiol 2008;6:67–78.Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 88.e1–88.e6
